Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$44.37 USD
+2.10 (4.97%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $44.43 +0.06 (0.14%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RYTM 44.37 +2.10(4.97%)
Will RYTM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for RYTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates
Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
RYTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
Moderna (MRNA) Surges 6.2%: Is This an Indication of Further Gains?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Misses Revenue Estimates
Other News for RYTM
Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Tracking Baker Brothers Portfolio - Q1 2024 Update
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Corcept Therapeutics (CORT) and Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024